Table 2.
Subgroup analyses for vitamin E in preventing chemotherapy-induced peripheral neuropathy
| Outcome | No. of patients | No. of studies | Vitamin E | Control subjects | RR (95% CI) | p-value | I2 (%) |
|---|---|---|---|---|---|---|---|
| All included studies | 353 | 6 | 59 of 174 | 81 of 179 | 0.55 (0.29–1.05) | 0.07 | 77 |
| High-quality trials (low risk of bias) | 264 | 3 | 49 of 131 | 48 of 133 | 1.03 (0.59–1.80) | 0.92 | 62 |
| Vitamin E vs. placebo | 264 | 3 | 49 of 131 | 48 of 133 | 1.03 (0.59–1.80) | 0.92 | 62 |
| Multicentre study | 230 | 2 | 34 of 113 | 37 of 117 | 0.50 (0.06–4.27) | 0.53 | 79 |
| Cisplatin-based formula | 98 | 3 | 8 of 44 | 33 of 54 | 0.31 (0.17–0.58) | 0.0002 | 0 |
RR – relative risk; CI – confidence interval